These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 21913406)
1. [Experience with use of immunomodulators in treatment of tonsillitis developed at the background of preimmunization by TEOVac]. Bondarev VP; Mel'nikov SA; Shagarov EE; Chernikova NK; Gutorova VI; Dorokhina TV; Bondareva TA Antibiot Khimioter; 2011; 56(3-4):32-4. PubMed ID: 21913406 [TBL] [Abstract][Full Text] [Related]
2. [Estimation of possible use of interferon inductors for prevention of postvaccional reactions to TEOVac in animal models]. Chernikova NK; Bondareva TA; Borisevich SV; Dorokhina TV; Khmelev AL; Shagarova NV Antibiot Khimioter; 2011; 56(9-10):19-22. PubMed ID: 22586899 [TBL] [Abstract][Full Text] [Related]
3. [Use of antibiotics in the treatment of ulceronecrotic tonsillitis due to vaccination by tabletted smallpox vaccine]. Bondarev VP; Borisevich IV; Mel'nikov SA; Kaskov AV; Shagarov EE; Chernikova NK; Dorokhina TV; Rylov AV; Bondareva TA; Terent'ev AI Antibiot Khimioter; 2010; 55(3-4):21-3. PubMed ID: 20695204 [TBL] [Abstract][Full Text] [Related]
5. Adverse events after smallpox immunizations are associated with alterations in systemic cytokine levels. Rock MT; Yoder SM; Talbot TR; Edwards KM; Crowe JE J Infect Dis; 2004 Apr; 189(8):1401-10. PubMed ID: 15073677 [TBL] [Abstract][Full Text] [Related]
6. [Peroral immunization--a method for enhancing the safety of the recombinant vector (the vaccinia virus)]. Podkuĭko VN; Vorob'ev AA; Krasnianskiĭ VP; Patrikeev GT; Mikhaĭlov VV; Dorokhina TV; Makhlaĭ AA; Dykanov GA Vestn Ross Akad Med Nauk; 1993; (2):39-44. PubMed ID: 7688619 [TBL] [Abstract][Full Text] [Related]
7. Determination of immunity to vaccinia virus by using diluted inactivated vaccinia vaccine solution for skin testing. Somekh E; Smetana Z; Tanay A; Dalal I; Babai I; Mendelson E Vaccine; 2004 Dec; 23(3):321-4. PubMed ID: 15530675 [TBL] [Abstract][Full Text] [Related]
8. [Immunomodulators for the prevention and treatment of acute respiratory infections: efficacy of azoximer bromide]. Bulgakova VA Ter Arkh; 2014; 86(12):92-7. PubMed ID: 25804048 [TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine. Vollmar J; Arndtz N; Eckl KM; Thomsen T; Petzold B; Mateo L; Schlereth B; Handley A; King L; Hülsemann V; Tzatzaris M; Merkl K; Wulff N; Chaplin P Vaccine; 2006 Mar; 24(12):2065-70. PubMed ID: 16337719 [TBL] [Abstract][Full Text] [Related]
10. [Mechanism of action and clinical effectiveness of immunomodulator glucosaminylmuramyl dipeptide (licopide)]. Ivanov VT; Andronova TM; Nesmeianov VA; Pinegin BV; Ledger P; Bomford R; Khaitov RM Klin Med (Mosk); 1997; 75(3):11-5. PubMed ID: 9229604 [No Abstract] [Full Text] [Related]
11. Inadvertent inoculation as an adverse event following exposure to vaccinia virus: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Wenger P; Oleske JM; Kohl KS; Fisher MC; Brien JH; Graham PL; LaRussa PS; Lipton S; Tierney B; Vaccine; 2007 Aug; 25(31):5754-62. PubMed ID: 17537553 [No Abstract] [Full Text] [Related]
12. Smallpox vaccination of eczema patients with attenuated live vaccinia virus. Kempe CH Yale J Biol Med; 1968 Aug; 41(1):1-12. PubMed ID: 5683825 [No Abstract] [Full Text] [Related]
13. The rational development of biological response modifiers. Talmadge JE Biotherapy; 1992; 4(3):177-8. PubMed ID: 1599800 [No Abstract] [Full Text] [Related]